A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
| 対象疾患 | Multiple Sclerosis, Relapsing-Remitting |
|---|---|
| 相 | 第3相 |
| スポンサー | Mapi Pharma Ltd. |
| ステータス | 完了 |
| 参加者数 | 1,016 名 |
| 介入（薬剤） | GA Depot |
| 開始日 | 2019年9月19日 |
| 完了日 | 2023年6月13日 |
| 結果公開日 | 2026年8月5日 |
概要
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks
Annualized Relapse Rate (ARR)
| Early Start: GA Depot 40 mg | 0.182 ± 0.022 Relapses per participant per year |
|---|---|
| Delayed Start: Placebo | 0.260 ± 0.029 Relapses per participant per year |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
- A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
- Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi